文献速递消化道肿瘤与早癌消化内镜

系统综述:Lynch综合征个体结直肠肿瘤的非内镜监测

Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2022-02-18

该系统综述检索MEDLINE和EMBASE,评估Lynch综合征患者结直肠癌及腺瘤的非内镜筛查方法。共纳入7项研究,影像学技术无法检出小于10mm的结直肠癌和(进展期)腺瘤;生物标志物研究存在样本量小、偏倚风险高或腺瘤患病率低等问题,作者认为这些非侵入性标志物可能具有潜力,应优先开展(临床)前研究。

要点

  • CT结肠成像和MR结肠成像均无法检出小于10mm的结直肠癌和(进展期)腺瘤。
  • 甲基化SEPTIN9对结直肠癌的敏感性为70%,hMLH1为91%,BAT-26为33%。
  • 甲基化SEPTIN9、FIT和BAT-26对结直肠癌和/或腺瘤的特异性为94-100%。

核心结论

  • 影像学技术不适用于Lynch综合征的结肠监测,而生物标志物研究不足。
  • 作者认为这些非侵入性标志物(无论是否联合)可能对该人群具有潜力。
  • 作者提出应优先开展该领域的(临床)前研究。

研究设计与样本

  • 系统综述,检索MEDLINE和EMBASE,纳入研究Lynch综合征中结直肠癌和腺瘤检测的影像学技术和生物标志物的研究。
  • 使用QUADAS-2工具对纳入研究进行质量评估。
  • 1332篇筛选文献中7篇符合纳入标准。

主要发现

  • 2项研究评估CT结肠成像或MR结肠成像,两种技术均无法检出结直肠癌和小于10mm的(进展期)腺瘤。
  • 5项研究评估血浆甲基化SEPTIN9、粪便免疫化学检测(FIT)、粪便肿瘤DNA标志物(BAT-26、hMLH1、p53、D9S171、APC、D9S162、IFNA和DCC)及粪便微生物组作为筛查方式。
  • 结直肠癌敏感性从33%(BAT-26)到70%(甲基化SEPTIN9)到91%(hMLH1)。
  • 甲基化SEPTIN9、FIT和BAT-26对结直肠癌和/或腺瘤观察到高特异性(94-100%)。
  • 腺瘤患者粪便中Desulfovibrio富集。

关键数值与推荐

  • 结直肠癌敏感性:BAT-26为33%,甲基化SEPTIN9为70%,hMLH1为91%。
  • 甲基化SEPTIN9、FIT和BAT-26对结直肠癌和/或腺瘤的特异性为94-100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 所有纳入研究均存在样本量小、偏倚风险高/不明确和/或腺瘤患病率低的特点。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Individuals with Lynch syndrome are at high risk for colorectal cancer (CRC). Regular colonoscopies have proven to decrease CRC incidence and mortality. However, colonoscopy is burdensome and interval CRCs still occur. Hence, an accurate, less-invasive screening method that guides the timing of colonoscopy would be of important value. AIM: To outline the performance of non-endoscopic screening modalities for Lynch-associated CRC and adenomas. METHODS: Systematic literature search in MEDLINE and EMBASE to identify studies investigating imaging techniques and biomarkers for detection of CRC and adenomas in Lynch syndrome. The QUADAS-2 tool was used for the quality assessment of included studies. RESULTS: Seven of 1332 screened articles fulfilled the inclusion criteria. Two studies evaluated either CT colonography or MR colonography; both techniques were unable to detect CRC and (advanced) adenomas <10 mm. The other five studies evaluated plasma methylated-SEPTIN9, faecal immunochemical test (FIT), faecal tumour DNA markers (BAT-26, hMLH1, p53, D9S171, APC, D9S162, IFNA and DCC) and faecal microbiome as screening modalities. Sensitivity for CRC varied from 33% (BAT-26) to 70% (methylated-SEPTIN9) to 91% (hMLH1). High specificity (94-100%) for CRC and/or adenomas was observed for methylated-SEPTIN9, FIT and BAT-26. Desulfovibrio was enriched in the stool of patients having adenomas. However, all these studies were characterised by small populations, high/unclear risk of bias and/or low prevalence of adenomas. CONCLUSIONS: Imaging techniques are unsuitable for colon surveillance in Lynch syndrome, whereas biomarkers are understudied. Having outlined biomarker research in Lynch-associated and sporadic CRC/adenomas, we believe that these non-invasive markers may hold potential (whether or not combined) for this population. As they could be of great value, (pre-)clinical studies in this field should be prioritised.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. van Liere ELSA, de Boer NKH, Dekker E, et al. Systematic review: non-endoscopic surveillance for colorectal neoplasia in individuals with Lynch syndrome. Aliment Pharmacol Ther. 2022. PMID: 35181895. doi:10.1111/apt.16824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。